A randomized, open-label, multicenter, phase 2 clinical trial to explore the safety and efficacy of sepranolone in pediatric and adult patients with Tourette Syndrome.
Latest Information Update: 11 Feb 2025
At a glance
- Drugs Sepranolone (Primary)
- Indications Gilles de la Tourette's syndrome
- Focus Therapeutic Use
- Sponsors Asarina Pharma
Most Recent Events
- 06 Feb 2025 Results presented in the Relmada Therapeutics Media Release.
- 25 Mar 2023 Status changed to completed.
- 13 Nov 2019 New trial record